Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 11 de 11 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
2. Cita con resumen
Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncology 2016:13 de octubre. [Ref.ID 100814]
3. Cita con resumen
Anónimo. Pfizer announces planned acquisition of Medivation for $14 billion. DIA Daily 2016:1. [Ref.ID 100588]
5. Cita con resumen
Anónimo. Enzalutamide et cancer de la prostate métastasé. Prescrire 2015;35:653-4. [Ref.ID 99711]
7.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim C-S, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin M-E, Venner PM, Tombal B, for the PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33. [Ref.ID 97836]
8. Cita con resumen
Anónimo. Enzalutamide. Prescrire 2014;34:330-4. [Ref.ID 97555]
10.Tiene citas relacionadas
Vogelzang NJ. Enzalutamide - A major advance in the treatment of metastatic prostate cancer. N Engl J Med 2012;367:1256-7. [Ref.ID 93804]
11.Tiene citas relacionadas
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de With R, Mulders P, Chi KN, Shore ND, Amstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, for the AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97. [Ref.ID 93802]
Seleccionar todas
 
 1 a 11 de 11